It is not known if the features of GVHD following reducedintensity conditioning (RIC) allograft differ from those following a conventional allograft. Ascites, pleural and pericardial effusions have been previously reported following myeloablative allografts. VOD, infections, cardiac insufficiency, 1 postconditioning and G-CSF toxicity, 2 and disease relapse 3 can cause effusions after BMT. Extensive chronic GVHD (cGVHD) with laboratory features of autoimmunity has been found to be a cause of sterile effusions. [4][5][6][7] In a review of 1905 patients, Seber et al 8 evaluated seven cases presenting with large recurrent sterile pleural and/or pericardial effusions following myeloablative alloBMT and felt that these were possibly associated with acute/chronic GVHD and CMV infection. Silberstein et al 9 recently described a patient with Hodgkin's disease who developed extensive cGVHD following an RIC allograft and DLI, and presented with polymyositis, polyserositis with large pericardial effusion and constrictive pericarditis.
It is not known if the features of GVHD following reducedintensity conditioning (RIC) allograft differ from those following a conventional allograft. Ascites, pleural and pericardial effusions have been previously reported following myeloablative allografts. VOD, infections, cardiac insufficiency, 1 postconditioning and G-CSF toxicity, 2 and disease relapse 3 can cause effusions after BMT. Extensive chronic GVHD (cGVHD) with laboratory features of autoimmunity has been found to be a cause of sterile effusions. [4] [5] [6] [7] In a review of 1905 patients, Seber et al 8 evaluated seven cases presenting with large recurrent sterile pleural and/or pericardial effusions following myeloablative alloBMT and felt that these were possibly associated with acute/chronic GVHD and CMV infection. Silberstein et al 9 recently described a patient with Hodgkin's disease who developed extensive cGVHD following an RIC allograft and DLI, and presented with polymyositis, polyserositis with large pericardial effusion and constrictive pericarditis.
We performed an RIC PBSCT from an HLA-identical brother in a 52-year-old woman with CLL Rai IV. Conditioning consisted of fludarabine, busulphan and ATG. Cyclosporin A (CsA) as GVHD prophylaxis was started on DÀ2. Engraftment was fast but lymphocytosis increased rapidly with 40 000 lymphocytes/mm 3 in blood and 52% in the marrow on D þ 30. At that time, the patient had 45% donor CD3 þ cells in the blood. The posttransplant period was uneventful except for skin acute GVHD (aGVHD) grade 2 from D þ 15 that was effectively treated with a short-course prednisolone. The patient was discharged from the hospital 1 month after transplantation without aGVHD and Karnovsky index of 100%. Owing to persistent CLL, CsA was withdrawn on D þ 63. On D þ 70, the patient developed grade 4 skin and grade 3 gut aGVHD. Combined immunosupression with CSA, steroids and an anti-IL2-receptor antibody was started with skin GVHD amelioration, but intestinal symptoms did not improve. On D þ 80, patient started complaining of abdominal distension. Ultrasound on D þ 84 confirmed the presence of ascites (approximately 2 l) with normal flow in the portal vein without hepatosplenomegaly. Bilirubin and transaminases were normal. Usual causes of ascites (VOD, cardiac, bacterial, tuberculosis, viral, fungal causes and significant hypoalbuminemia with concomitant fluid retention) were excluded by appropriate tests. Autoantibodies that are commonly present in cGVHD (antinuclear (ANA), antismooth muscle, antimitochondrial, anti-RO/ SSA, anti-La/SSB, anti-SM, anti-Scl70, antithyroid, anti-LKM, Farr test) were all negative. During the next 5 months, the patient was drained of 1-4 l of ascitic fluid on five occasions (Table 1 ). The first paracentesis at þ 3 months demonstrated clear ascitic fluid with a protein level of 25 g/l and 96% of lymphocytes. The cellular composition of the ascitic fluid was similar in all aspirates: cytological and phenotypic analysis revealed high prevalence of T cells (86%) and no CLL. Donor origin of the ascitic T cells was confirmed by FISH (98% 46XY). Interestingly, at that time, blood and marrow showed heavy infiltration with monoclonal CLL B cells. In spite of significant residual disease, the amount of donor chimaerism was on the rise in the blood (48% of all cells and 94% of CD3 þ cells).
Gut GVHD persistence with ascites accumulation resulted in a second paracentesis at 4 months. BM aspiration performed simultaneously revealed signs of the GVL effect with a significant reduction of CLL-related cells. At the end of the 5th month, skin and gut GVHD resolved with simultaneous disappearance of ascites. Donor's CD3 þ chimaerism remained at 95%, but immunosuppression led to inhibition of the GVL effect: marrow CLL infiltration increased to 56% with the rise of blood B-CLL counts. Transjugular liver biopsy (TJLB) showed CD19 þ infiltration with minimal signs of GVHD and no evidence of EBV. The steroid dose was reduced and CsA was substituted with MMF. The patient was discharged from the hospital with no signs of active GVHD on day þ 150. After 10 days, she was readmitted with acute reactivation of grade 3 gut GVHD and recurrence of ascites. The second 'wave' of GVHD was treated in the same manner as the first and again resulted in the near complete resolution of intestinal GVHD manifestations and ascites. Marrow aspirate at þ 6.5 months showed reduction in lymphoid infiltration to 23%. Second TJLB revealed GVHD signs with minimal CD19 þ lymphocyte infiltration. At þ 7 months, patient developed acute cholecystitis with Gram-negative septic shock requirng temporary discontinuation of immunosuppression. At þ 8 months, the signs of intestinal and hepatic GVHD as well as ascites recurred. A combination of prednisolone, CsA and MMF was used, but the patient's condition deteriorated progressively. She died at þ 9 months of progressive GVHD and concomitant infective complications.
The appearance of ascites in our patient was associated with persistence of high grade of intestinal, but not liver, GVHD. We found a chronological correlation between appearance/resolution of ascites and the intensity of gut GVHD. It is not clear if ascites was a secondary peritoneal reaction of intestinal GVHD or developed due to direct interactions between activated donor's T cells and recipient's mesothelium. Although the classically recognised target organs of aGVHD are skin, gastrointestinal tract, liver and lymphatic organs, other tissues may also be involved.
10 Histologically, it is normally characterised by infiltration of tissue by donor's lymphoid cells and destruction of epithelium. The latter may disrupt the usually protective cutaneous and mucosal barriers with acute alteration of their permeability, which in gut GVHD causes profuse watery diarrhoea. It is possible that excessive bidirectional T-cell infiltration of bowel wall and mesenterium in gut aGVHD led to alteration of permeability not only of mucosal, but also serosal barriers with excessive production of ascitic fluid. It is possible that the donor's T cells that we found in the ascitic fluid migrated across the intestinal wall. In our case, the presence of ascites could indicate the extent of T-cell infiltration. Another important observation is the dynamics of posttransplant graft/residual leukaemia interactions. It confirms that the loss of GVL effect in the presence of full donor CD3 þ chimaerism can be transient and reversible after discontinuation of intensive immunosuppression. In summary, we report a case of isolated ascites as an unusual presentation of GVHD after an RIC PBSCT from an HLA-identical sibling donor for resistant CLL. 
